Thioredoxin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
* '''Trx C,M,X,Y''' are found in prokaryotes.<br />
* '''Trx C,M,X,Y''' are found in prokaryotes.<br />
* '''Trx F,H,O''' are found in eukaryotes.<br />
* '''Trx F,H,O''' are found in eukaryotes.<br />
-
Há uma gama de estratégias utilizadas pelo organismo hospedeiro na tentativa de defesa contra a invasão do patógeno. Dentre esses, há a liberação de oxidantes, como as espécies reativas de oxigênio (EROs) que em concentrações fisiológicas definidas, atuam como mensageiros de sinalização. No entanto, em concentrações suprafisiológicas, sua reatividade traz consequências celulares deletérias, ocasionando danos às macromoléculas como proteínas, lipídios e DNA, desta forma, prejudicando a homeostase do sistema (SIES, 1985). Assim sendo uma alternativa utilizada para inibir o patógeno e impedir a infecção do organismo.
+
There are a range of strategies used by the host organism in an attempt to defend itself against pathogen invasion. Among these is the release of oxidants, such as reactive oxygen species (ROS), which at defined physiological concentrations act as signaling messengers. However, in supraphysiological concentrations, their reactivity has deleterious cellular consequences, causing damage to macromolecules such as proteins, lipids and DNA, thus impairing the system's homeostasis (SIES, 1985). It is therefore an alternative used to inhibit the pathogen and prevent infection of the organism.
 +
 
== Relevance ==
== Relevance ==

Revision as of 11:57, 23 June 2025

Human thioredoxin (PDB entry 1ert)

Drag the structure with the mouse to rotate

References

  1. Gleason FK, Holmgren A. Thioredoxin and related proteins in procaryotes. FEMS Microbiol Rev. 1988 Dec;4(4):271-97. PMID:3152490
  2. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, Nakajima Y, Ishikawa H, Mitsuyoshi H, Okanoue T, Kashima K, Nakamura H, Yodoi J. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol. 2003 Jan;38(1):32-8. PMID:12480557
  3. Burke-Gaffney A, Callister ME, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci. 2005 Aug;26(8):398-404. PMID:15990177 doi:http://dx.doi.org/10.1016/j.tips.2005.06.005
  4. Weichsel A, Gasdaska JR, Powis G, Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure. 1996 Jun 15;4(6):735-51. PMID:8805557
Personal tools